This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

GPC Biotech Takes Satraplatin Off Fast Track

GPC Biotech's (GPCB) stock rebounded Monday after the company withdrew its new-drug application (NDA) for accelerated approval of prostate cancer drug satraplatin.

Last week the Oncologic Drugs Advisory Committee unanimously recommended that the Food and Drug Administration wait for survival data from the SPARC trial before deciding whether to approve the drug, which was licensed to GPC by Spectrum Pharmaceuticals (SPPI - Get Report).

The data are expected in six months but are dependent on the death rates in the trial, a difficult factor to predict. "We look forward to receiving the overall survival data from the SPARC trial and to the resubmission of the NDA to the FDA next year," said Spectrum's Chief Scientific Officer Luigi Lenaz.

A brief by ODAC preempting last week's meeting -- which caught some investors by surprise with a discouraging outlook for the accelerated approval of satraplatin -- followed by the panel's unanimous decision, sent shares of both GPC and Spectrum tumbling. But upon withdrawing the NDA Monday, GPC gained $1.57, or 15.2%, to $11.92, and Spectrum gained 5 cents, or 1.3%, to $4.05.

Spectrum also said Friday that the European Medicines Agency accepted an application for marketing authorization for satraplatin in combination with prednisone to treat prostate cancer patients who've failed chemotherapy. Pharmion (PHRM) has the right to market the satraplatin in Europe.

Pharmion was up 5 cents, or 0.2%, at $24.47 in recent trading Monday.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
SPPI $4.42 0.00%
AAPL $94.27 0.00%
FB $101.00 0.00%
GOOG $684.12 0.00%
TSLA $143.67 0.00%


Chart of I:DJI
DOW 15,914.74 -99.64 -0.62%
S&P 500 1,851.86 -0.35 -0.02%
NASDAQ 4,283.5920 +14.8290 0.35%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs